We tested the hypothesis that amino acid substitutions in specific positions within Class I heavy chain would have a different impact on unrelated bone marrow transplantation (UD-BMT) outcome. 163 donor-recipient pairs, all matched for DRB1/3/4/5, DQA1, and DQB1 loci were typed by sequence based typing (SBT) for the HLA-A, -B, and -C loci. 60 pairs were also matched at Class I, whereas 103 pairs had one or more mismatches at Class I loci. The impact on the outcome of different amino acid substitutions was analyzed. The only variable predictive of severe acute Graft versus Host Disease (aGvHD) in multivariate Cox analysis was substitution at position 116. Variables predictive of transplant-related mortality (TRM) in a multivariate Cox analysis were number of cells infused and amino acid substitution at position 116. The actuarial risk of aGvHD grade III-IV at 100 days, and of TRM and overall survival at 3 years were significantly increased for transplants with substitutions at position 116 (n=68) compared to other pairs (n=95). In conclusion these data suggest that substitutions at position 116 of Class I heavy chain increase the risk of acute GvHD and TRM in unrelated donor transplant.
We tested the hypothesis that amino acid substitutions in specific positions within Class I heavy chain would have a different impact on unrelated bone marrow transplantation (UD-BMT) outcome. 163 donor-recipient pairs, all matched for DRB1/3/4/5, DQA1, and DQB1 loci were typed by sequence based typing (SBT) for the HLA-A, -B, and -C loci. 60 pairs were also matched at Class I, whereas 103 pairs had one or more mismatches at Class I loci. The impact on the outcome of different amino acid substitutions was analyzed. The only variable predictive of severe acute Graft versus Host Disease (aGvHD) in multivariate Cox analysis was substitution at position 116. Variables predictive of transplant-related mortality (TRM) in a multivariate Cox analysis were number of cells infused and amino acid substitution at position 116. The actuarial risk of aGvHD grade III-IV at 100 days, and of TRM and overall survival at 3 years were significantly increased for transplants with substitutions at position 116 (n=68) compared to other pairs (n=95). In conclusion these data suggest that substitutions at position 116 of Class I heavy chain increase the risk of acute GvHD and TRM in unrelated donor transplant.
ON THE EFFICIENCY OF OPTIMIZED PROSPECTIVE TYPING STRATEGIES FOR DONOR REGISTRIES
Carlheinz Müller Zentrales Knochenmarkspender-Register für die Bundesrepublik Deutschland, Ulm, Germany, A reasonable measure for the quality of the composition of a registry is the fraction of patients finding at least one matching donor on the first search of the registry. This indicates to which extent the phenotype spectrum of population is covered by the registry. For a population Hardy-Weinberg-Equilibrium, this "population coverage" can be estimated using the size of the registry and the HLA haplotype frequencies. Due to limited funds, many registries contain a majority of donors which are only typed for HLA-A and -B. We have designed an algorithm to select such donors for HLA-DRB1-typing by their HLA-A,Bphenotype so that after a defined number of typings performed the expected population coverage is maximized. This algorithm uses HLA haplotype frequencies to estimate absolute HLA-A,B,DR-phenotype frequencies as well as conditional distributions of HLA-DRB1 subtypes for each HLA-A,B-phenotype. Then, taking into account the current registry composition, a sequence of donors to be typed for HLA-DRB1 can be established optimizing the chance of a patient to have an HLA-A,B,DRB1-matching donor instantly. A computer simulation of this process revealed that our strategy can save initially up to 60% of typing costs over a random selection of HLA types and that the gain in efficiency will then remain between 15% and 25% until over 80% of the donors are fully typed. Since HLA typing costs are the largest burden on the budget of most registries this strategy can have a substantial economic impact. Even following HLA-identical stem cell transplantation, graft versus host disease (GvHD) can occur. In this situation, recognition of foreign minor histocompatibility antigens (minor Histocompatibility Ag) by donor T cells is responsible for the disease. HLA-identical allogeneic T cell responses can be induced in vitro using dendritic cells. In this way, T cell clones specific for an H-Y minor Histocompatibility Ag associated with HLA-DQ beta1*0502 have been isolated. (Transplantation, 2001 (Transplantation, , 71: 1449 .
IN VITRO PRIMING OF HLA-IDENTICAL T CELLS WITH ALLOGENEIC DENDRITIC CELLS ALLOWS IDENTIFICATION
Using HLA-DQ beta1*0502-expressing female B EBV-LCL transfected with various H-Y genes, we here show that these T cell clones are specific for a peptide encoded by DBY The same peptide was also recognized by an HLA-DQ beta1*0501-restricted H-Y specific T cell clone This T cell clone was generated in vitro from another HLA-identical sibling pair. The peptide corresponds to the epitope of a T cell clone isolated in vivo from a patient suffering from GvHD (M Vogt et al Blood, 2002 99:3027) . Both the DQ beta1*0501 -and the DQ beta1*0502-restricted H-Y specific T cell clones used the same V beta gene rearrangement.
In conclusion, our results demonstrate that in vitro stimulation of HLAidentical T cells with dendritic cells can result in the isolation and characterization of minor Histocompatibility peptide. Moreover, these results suggest that this methodology could favour the isolation of immunodominant HLA-class II-associated minor Histocompatibility Ag.
This Modulation of human dendritic cells by triggering through CD40 or LPS in the presence of the corticosteroid dexamethason, lead to a low expression of costimulatory -and MHC class II molecules, low IL-12 production but a high secretion of IL-10. We explored the possibility to tolerize T cells in vitro and in vivo with these alternatively activated antigen-bearing DC.
These alternatively activated DC displayed a decreased allostimulatory potential for IFN-producing cells but induced IL-10 producing T-cells, that were able to downregulate the alloimmune response of both CD4+ and CD8+ positive T-cells.
Similar results were obtained with mouse dendritic cells. Injection of alternatively matured C57BL/6 DC (H-2b) into BALB/c mice (H-2d) leads to a reduced IFN-production in vitro, whereas the number of IL-10 producing cells was increased. Furthermore, transplantation of fully H-2 mismatched skin grafts (C57BL/6), led to a significantly prolonged survival compared to that of either mature DC pretreated mice or untreated mice. This effect was antigenspecific, as third party-reactive allo responses were not affected. The present data suggest that "tolerogenic" DC may become an attractive tool for the induction of transplantation tolerance in the clinical setting.
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Abstract Session II -Immune Response IMPACT Several transplantation approaches with MHC I down-regulated grafts have been employed. A novel promising method to inhibit the MHC I surface expression is the utilization of intracellularly expressed antibodies (intrabodies). Intrabodies are able to bind and retain MHC I molecules inside the cell. We have generated lentiviral vectors encoding for an anti-MHC I intrabody directed against a monomorphic epitope, which was either cloned as fusion protein with EGFP or as single protein. Rat Aortic Endothelial Cells (RAEC) were isolated and used as target cells for the gene transfer. MHC I surface expression was measured 48 h after gene transfer or the selection of stable cell clones. The effect of the MHC I down-regulation on RAEC was tested in cytotoxicity assays of allo-stimulated effector T cells (Calcein-release assay).
Intrabody-expressing RAEC exhibited strongly reduced MHC I expression concerning percentage of MHC I expressing cells and fluorescence intensity in contrast to Mock-cells. Furthermore this MHC I down-regulatory effect was stable over several passages. In comparison to unmodified cells, RAEC with reduced MHC I levels displayed less sensitivity to allogeneic cytotoxic T cells which were in vitro generated by MLR (day 5) of MHC I different rat strains (WF/ LEWIS). The killing rate was reduced by 15-25 % compared to the rate of Mock-cells.
On the basis of these results we set to determine by in vivo studies whether the intrabody expression could prolong the survival of allogeneic RAEC on the luminal surface of vascular grafts.
IL-15 AND COGNATE ALLOGENEIC STIMULATION SUCCESSFULLY EXPAND DE NOVO INDUCED HUMAN DONORSPECIFIC REGULATORY CD4+ T-CELLS THAT ONLY SHOW SUPPRESSION UPON ALLOSPECIFIC ACTIVATION
Hans JPM Koenen, Esther Fasse and Irma Joosten Department for Bloodtransfusion and Transpantation Immunology, University Medical Center Nijmegen, The Netherlands.
Immunosuppressive regulatory T-cells are considered relevant for immunotherapy. To obtain sufficient cell numbers for clinical application, ex vivo expansion without loss of suppressor function is crucial. Previously, we reported expansion of human anergic regulatory T-cells without loss of anergy by allospecific stimulation in the presence of exogenously added IL-2. IL-15, like IL-2, is a T-cell growth factor that in contrast to IL-2 stimulates survival of T-cells. Here, we studied whether IL-15 could indeed be exploited as a superior growth factor of de novo induced human CD4+ anergic regulatory T-cells.
Anergic regulatory CD4+ T-cells were generated by CD86 and CD40 costimulation blockade of primary mixed lymphocyte reactions. Interestingly, the de novo induction of suppressive regulatory T cells required the presence of naturally occuring CD4+CD25+ regulatory T cells.
Next, IL-15 as compared to IL-2, was investigated with respect to expansion and function of these de novo induced anergic regulatory CD4+ T-cells. Optimal expansion required cognate allogeneic stimulation in the presence of exogenous IL-15. IL-15 resulted in enhanced survival that was paralleled by an increased number of Bcl-2 expressing cells. Moreover, IL-15 induced a distinc type of anergy characterized by hyper-reactivity to IL-15, and hence resulted in improved expansion. Notably, IL-15 expanded regulatory CD4+ T-cells were superior immunosuppressors of both naive and memory T-cells. Immunosuppression required alloantigen specific stimulation, appearedirradiation resistant and was independent of IL-10, TGF or CTLA-4 interactions. IL-15 expanded regulatory CD4+ T-cells were stable suppressors that did not affect autologous recall responses in the absence of allogeneic MHC.
Thus, IL-15 expanded de novo induced human anergic regulatory CD4+ Tcells have the potential to be used for antigen specific immunotherapy.
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PRE-TREATMENT OF HUMAN LYMPHOCYTES WITH CD31 PEPTIDE INHIBITS CELLULAR PROLIFERATION IN MIXED LYMPHOCYTE CULTURE
G Cavanagh1, P Middleton2, A Dickinson2 and C Chapman1 National Blood Service, Newcastle; University of Newcastle upon Tyne CD31 is a 130-kDa transmembrane glycoprotein expressed by: endothelial cells; platelets; monocytes; neutrophils and certain T cell subsets. The CD31 extracellular domain has six immunoglobulin(Ig)-homology domains that share sequence similarity with cellular adhesion molecules (CAM). We have shown that pre-treatment of human blood lymphocytes with a CD31 peptide targeted at the polymorphic position (exon 8 -Codon 563 (Asn/Ser)) of the membrane proximal Ig domain 6 strongly inhibits proliferation in mixed lymphocyte culture. Effect of this CD31 peptide was shown to be dose dependent with an optimal concentration between 200-400ng/ul. Matching of CD31 peptide with lymphocyte CD31 genotype in a homophilic manner was also required for inhibition. A scrambled form of the peptide was used during experimentation as a control. This had no effect on proliferation.
Further work is currently being undertaken to elucidate the mechanism of inhibition. This may simply result from interference in the cellular adhesion that occurs during lymphocyte activation. However, binding of peptide at this position may result in tyrosine phosphorylation of the immunoreceptor tyrosinebased inhibitory motif (ITIM) in the cytoplasm of CD31 leading to attenuation of intracellular signalling required for activation.
These data suggest an important functionally important domain, of the CD31 molecule, in lymphocyte activation. This may have important therapeutic implications in transplantation.
HLA-G AS A MODULATOR OF PERIPHERAL NK AND T-CELL RESPONSES.
A van der Meer1, PE Emmer1, B van Cranenbroek1, MJ van Lierop2 and I Joosten. 1Dept. of Bloodtransfusion and Transplantation Immunology, UMC Nijmegen and 2NV.Organon, the Netherlands, a.vandermeer@utdts.azn.nl HLA-G is a non-classical HLA class I molecule that is expressed at the foetalmaternal interphase and modulates the uterine immune response by interaction with maternal NK cells and T-cells. RNA encoding for HLA-G has now also been found in several other tissues and receptors for HLA-G are present on peripheral NK cells, T-cells, B-cells and monocytes. Others have shown that HLA-G expression in heart allografts was associated with a reduced number of rejection episodes. We were interested to see whether HLA-G could have an immunoregulatory effect on peripheral T and NK cell alloresponses.
To study the effect of membrane-bound HLA-G on the allorespons, 721.221 B-LCL cells were transfected with mHLA-G (G1) and used in a co-culture with peripheral blood mononuclear cells or purified T-or NK cells. Several aspects of NK and T-cell function were measured, i.e. proliferation, cytotoxicity and cytokine production. MHLA-G affected NK and T-cells differently. A high dose of mHLA-G inhibited proliferation and IFN and TNF production of T-cells. In contrast, NK cells were stimulated in their proliferative reponse as well as cytokine production, but inhibited in their cytotoxic activity. To study the effect of soluble HLA-G, a recombinant construct was made and expressed in CHO cells. The purified sHLA-G construct was then added to IL-2 or IL-15 stimulated PBMC cultures. SHLA-G differentially modulated T and NK cell responses albeit in a distinct fashion from mHLA-G. T-cells were inhibited in their proliferative response while NK cells were stimulated. The addition of sHLA-G lead to an increase in IFN and TNF production by PBMC. NK cell cytotoxicity was not affected by sHLA-G.
In conclusion, HLA-G clearly affects peripheral T and NK cell responses and these cells are modulated differently by HLA-G. Further-more, the mode of action of the membrane-bound form of HLA-G was different from that of the soluble form of HLA-G. These data shed light on the potential role of HLA-G in modulating a harmful alloresponse. Human blood DC are commonly divided into two distinct subsets. The myeloid DC (preDC1) are related to monocytes and can produce IL12 in response to bacterial stimuli. The plasmacytoid DC (preDC2) express high level of CD123 (IL3-R) and produce high amount of interferon upon virus infection. Both DC subtypes express HLA class II molecules. There is a large body of evidence demonstrating that HLA-DR transmits signal in APC. In a previous study we had demonstrated that HLA-DR mediated signals led to marked apoptosis in mature myeloid DC.
HLA-DR-MEDIATED APOPTOSIS
In this study, we addressed the question of the outcome of HLA-DR signals on DC2. Human blood preDC2 were obtained using a two step immuno-magnetic separation based on depletion of lineage specific markers and BDCA2 antibody (Miltenyi-Biotec). Lin-, HLA-DR+, CD123+ cells (purity >85%) were incubated either with isotypic control or HLA-DR (L243) Mo-Ab. No specific apoptosis induced by HLA-DR Mo-Ab was detected using annexin V (2.3%, n=2). By contrast, L243 induced apoptosis in mature IL3 or CD40-ligand induced DC2 (respectively 39.8%, n=3; 38%, n=3). Similarly to myeloid DC, z-VAD is not able to reverse mature DC2 apoptosis (40.7% versus 41%, n=2) leading to the hypothesis of an independent caspase mechanism.
Taken together these data lead to the hypothesis that signals generated via HLA-DR lead to the demise of mature professional APC, thereby providing a means of limiting the immune response.
POSITIVE SELECTION OF HLA CLASS II-RESTRICTED T-CELLS IN MURINE FETAL THYMIC ORGAN CULTURES
Sandra Reichstetter, John A. Gebe, Andy G. Farr, William W. Kwok HLA-DQ0302 is highly associated with increased risk to develop type 1 diabetes. HLA DQ0602 confers dominant protection. According to a popular hypothesis, DQ0602 is highly efficient in inducing negative and positive selection in the thymus, while, due to low peptide affinity of inherent instability, DQ0302 is less efficient in inducing thymic selection. This might lead to the escape of autoreactive T-cells into the periphery. However, direct evidence of allelic differences in the induction of thymic selection is lacking. Positive and negative thymic selection of mouse class II restricted CD4+ single positive cells has been shown previously in a thymic reaggregation culture using a immortalized mouse thymic epithelial cell line inducible for class II expression (ANV41.2). Transfecting this cell line with a HLA class II expression vector results in cells that can induce thymic selection of HLA restricted T-cells. The major drawback of thymic reaggregation cultures is the poor yield of single positive cells, which makes it impossible to evaluate subtle differences in thymic selection induced by different HLA class II alleles. Fetal Thymic Organ Cultures (FTOC) have long been a tool to study thymic development and selection. After direct injection of HLA transfected aNV41.2 cells into the lobes of thymi from embryonic day16, high numbers of CD4+single positive cells were recovered at day 10 of the FTOC. Stimulation of these CD4+ cells with anti-CD3 and anti-CD28 induced CD69 upregulation. We conclude that FTOC can provide an ideal tool to investigate allelic variations in thymic selection induced by different HLA class II alleles. It is well recognised that hematopoietic stem cells exist in umbilical cord blood (UCB). It is not clear whether mesenchymal stem cells (MSC) are also present as they are in bone marrow, and they are certainly not very well characterised. This study aims to identify this rare population in UCB by cell culture and characterise the cells by flow analysis.
Cells from whole UCB units were enriched for MSC by a negative selection technique that has been developed for use on human bone marrow (RosetteSep, Stem Cell Technologies). The enriched mononuclear cells were cultured and colonies of adherent spindle-shaped cells appeared after 2-4 weeks when there were 20x106 ccells or more in the initial culture. Once colonies had formed the cells grew to confluence after 1-2 weeks, and were passaged once a week.
Flow analysis revealed the lack of expression of CD34, CD45, CD14, CD133, CD106, CD166, HLA-G, HLA-DR,DP,DQ and VWF. There was a strong expression of CD90, CD105, CD13, CD29, CD44, CD73 and HLA-ABC. Interestingly, there was also strong intracellular expression of the intermediate filament protein, nestin.
When the cells were cultured in adipogenic stimulatory medium they developed lipid containing vacuoles that stained with Oil-Red O , and the transcription factor PPAR , which is expressed in adipose tissue, was detected by real-time PCR.
These results suggest that the adherent cells grown in culture from UCB resemble MSC from bone marrow. MSC have the potential to differentiate into many cell types that may have implications for therapy in a range of diseases.
MESENCHYMAL STEM CELLS SUPPRESS THE DIFFERENCIATION OF ALLOREACTIVE PRE-CTLS INTO CTL EFFECTORS
Clerc, Y. Bertrand, A. Farre, C. Galambrun, N. Philippe, L. Gebuhrer, D. Rigal, A. Eljaafari Cell Therapy Department, EFS-Rhone-Alpes, Lyon MSCs are likely to play an important role in the modulation of T cell responses towards polyclonal stimuli but also towards allogeneic grafts as reported by two recent studies (Di Nicola et al , Blood 2002: 99: 3838; Bartholomew Exp Hematol 2002, 30:42) . Therefore grafting allogeneic hematopoietic stem cells in the presence of MSCs could be an interesting perspective in the future. However, as opposed, with mouse MSCs, human MSCs express MHC class I molecules, albeit no MHC class II. Thus they cannot activate allo-reactive CD4+T cells, but an alloreactive cyotoxic response remains possible, which would then lead to their disappearance, once transplanted into allogeneic recipients.
Here we analyzed the susceptibility of MSCs to lysis by alloreactive CTLs.With this aim CTL precursor (CTLp) frequencies were measured following stimulation of T cells with either allogeneic mononuclear cells (MNC) or MSC originated from the same bone marrow human donor. Lysis of MSC was measured at day 10 of culture in standard chromium release assays. In addition, allogeneic PHA blast T cells or B-EBV lymphoblastoid cells generated from the same donor were used as positive controls of lysis.
Our results showed that when allogeneic MNC were used to stimulate T cells, a high CTLp frequency was detected towards MSC targets, assessing thus that MSCs can be recognized and lysed by CTL effectors. However, when MSC were used to stimulate allogeneic pre-CTLs, the CTLp frequencies were markedly altered whatever the targets used, ie: MSC, PHA blast T cells or B-EBV cells, demonstrating thus that MSCs are poor stimulators. Moreover, MSCs were able to suppress the activation of pre-CTLs by MNCs. Indeed, when graduated concentrations of MSC were added to MNC upon stimulation of alloreactive pre-CTLs, we observed an MSC cell dosedependent decrease in CTLp frequencies towards MSC targets. This inhibition of MSC lysis was partially overcomed by addition of 20 UI/ml exogenous rh-IL-2 to cultures, at day zero. In addition, this suppressive effect was totally reproduced when, instead of MSCs, supernatant harvested from MSC cultures was added to allogeneic MNC, upon stimulation of alloreactive T cells.
In summary , our results demonstrate that MSC can be recognized as targets by alloreactive CTLs, but are able to suppress differentiation of cytolytic T cell precursors into CTL effectors through secretion of soluble factors.This strongly suggests that, once transplanted, MSCs should not induce a cytolytic alloresponse. CD14-and CD34-derived DCs from human cord blood were investigated. CD14+-and CD34+-cells were isolated and generated to mature DCs. Both types of DCs were subsequently co-cultured with allogeneic naive TH cells or CTLs from healthy blood donors. T-cells were analysed for activation and proliferation as well as for intracellular cytokines. CD14-derived DCs showed significantly higher values for HLA-Class I, HLA-DM, CD80, CD86, CD9, CD40, whereas CD34-derived DC expressed more CD1a, CD4, CD11a. Furthermore, the ability for endocytosis of immature CD14-derived DCs was higher. Only a slight stimulation of CTLs by CD34-derived DCs was observed. TH cell stimulated with CD34-derived DCs produced more IL-4, whereas CTLs stimulated with CD14-derived DCs expressed more IFN-gamma. Using microarray hybridization analysis, different expression profiles of both cell types were observed.
PHENOTYPICAL AND IMMUNGENETICAL ANALYSIS OF CD14-AND CD34-DERIVED DENDRITIC CELLS (DCS)
Although both types of DCs showed the typical dendritic morphology and are positive for CD83 which has been accepted as the typical marker of dendritic cells, two different subpopulations of DCs could be observed with regard to the phenotypical, functional and immungenetical characteristics. CD14-derived DCs showed to be a stronger stimulator. CD34-derived DCs also stimulated naive T H cells. However, in comparison with proliferated T H cells stimulated by CD14-derived DCs a greater part of these proliferated T H cells seem to differentiate to T H 2 cells.
CD34 derived DCs might tolerize rather than stimulate cytotoxic T cells.
REGULATION OF MHC CLASS I EXPRESSION: ROLE OF CD99
Bernard Ghislaine, Albano L., Alberti I., Pourtein M., Bernard A. INSERM u 343 Immunology, Hôpital de l'Archet FRANCE, Nice
We have described CD99 as a heavily glycosylated 32 KD transmembrane molecule, it forms with Xga a new protein family. Triggering of CD99 on double positive human thymocytes induces a powerfull homotypic agregation and apoptosis of the subpopulation implicated in thymic selection, in mature T cells triggering of CD99 leads to enhancement of alpha 4 beta 1 affinity for its ligand VCAM-1. Two isoforms (a long form and a short one) obtained by alternative splicing have been described. We have recently shown that the two isoforms of CD99 are differentially expressed during T cell differentiation namely two isoforms (short and long) are present in double positive human thymocytes while only one isoform (long) remain expressed in human mature T cells. We have established that the presence of both forms is required for apoptosis and that the long form alone is sufficient to mediate adhesion. Recently it has been shown that the absence of CD99 is correlated with a lower level of expression of MHC class I. On the basis of these results the question we asked concern the potential role of CD99 structure on MHC class I expression. We have prepared CD99 negative Jurkat T cells and transfected them with cDNA from long, short or both CD99 isoforms, and we have obtained stable transfectants for each cell type. Using flow cytometry we have evaluated the level of MHC Class I expression on transfected cells. Expression of either long or short forms of CD99 is associated with a higher expression level (4 times ) of MHC Class I while transfection of both forms leads to MHC class I level similar to wild type Jurkat cells expression level. We have also prepared a CD99 cDNA where the two terminal leucines present in the cytoplasmic region were mutated respectively (LL/GA), when this mutated long form and the wild type short form were cotransfected MHC class I expression level remains higher compared to the wild type. In conclusion our results shown that CD99 is a non viral surface molecule able to act as a regulator of MHC class I expression. Previous data suggest that the non classical MHC class I antigen HLA-G is involved in immune tolerance in inhibiting NK and T functions. Dendritic cells (DC), professional antigen presenting cells, play also a key role during immune response. We have previously shown that DC may express HLA-G molecules under particular conditions such as pulmonary diseases. The aim of this work was to determinate the expression of HLA-G molecule during plasmacytoid and myeloid DC differentiation. HLA-G antigen expression was determined with two specific anti-HLA-G MoAbs 87g and MEM-G/9.
Plasmacytoid DC precursors (preDC2) were maturated in DC2 with IL3 or IL3 and CD40-L (n=3). Myeloid DC (DC1) were differentiated either from purified CD34+ progenitors cells (n=3) or fromperipheral monocytes (n=6) as previously described. No HLA-G expression was detected using immunocytochemistry on preDC2 and DC2. Nevertheless HLA-G molecules expression was found using flow-cytometry in 1 case of mature monocytederived DC and in 2 out of 4 cases of mature DC cultured with different cytokines combination at 48 hours. The protein was detected in 2 out of 3 cases of mature CD34-derived DC with one from immature stage. Moreover, HLA-G transcript appeared in CD34+ derived DC (n=3) compared to initial CD34+ cells using RT-PCR.
In conclusion, HLA-G expression is restricted to DC1. HLA-G expression on CD34-derived DC depends on both transcriptional and post-transcriptional mechanisms. In vitro characterisation of alloreactivity induced by isolated HLA antigens of interest is an important tool for the dissection of permissive and non-permissive HLA mismatches, one of the challenges of modern transplantation biology. The use of autologous antigen presenting cells (APCs) transfected with the HLA allele of interest is hampered by the scarce transfectability of professional APCs. In this study, we have circumvented this problem by use of autologous, PHA-activated T cell blasts as APCs. These cells are readily transfected with HLA alleles of interest by retroviral vector mediated gene transfer and subsequent purification of transduced cells by immunobead selection for the cell surface marker NGFr. These T cell blasts were capable of efficient and specific stimulation of alloresponses in mixed lymphocyte cultures The system is currently being used to study in vitro alloreactivity induced by permissive or non-permissive HLA DP 1 a lleles. Another application will be induction of single alloantigen specific regulatory T cells that could be useful for tolerance induction in mismatched haematological stem cell transplantation.
A NOVEL METHOD TO DETECT SOLUBLE HLA-G SECRETING CELLS Vera Rebmann, Annika Busemann, Monika Lindemann, and Hans Grosse-Wilde Institute of Immunology, University Hospital of Essen, Germany Soluble HLA-G (sHLA-G) molecules exist in the peripheral blood of healthy females and males, in cord blood and other body fluids. To identify sHLA-G secreting cells a rabbit antiserum (Ra-HLA-G/I-4) was generated against a peptide specific for Intron-4 being expressed by sHLA-G isoforms. By the use of Ra-HLA-G/I-4 for capturing and an anti-human 2-microglobulin mAb for detection a sHLA-G specific ELISpot assay was developed. To verify this sHLA-G ELISpot format the anti-HLA-G specific mAb MEM/G9 was used in parallel as capture reagent. The ELISpots were analysed in view of the spot numbers and the average of optical densities. For the sHLA-G positive tumor cell lines JEG3 and JUSO 12.5000 cells per well and a culture time of 24 h were found to be optimal for identification of distinct spots. In the presence of INF-α,β,γ and IL-10 the number of spots increase in a concentration dependent manner, reaching a maximum at an IFN-α,β,γ concentration of 500 U/ml and an IL-10 concentration of 50 ng/ml. Interestingly, the average of optical densities did not vary substantially in these experiments. So these results indicate that the number of sHLA-G secreting cells increased whereas the amount of secreted molecules per cell seemed to be stable. In addition monocytes, CD8 and CD4 T cells from 5 healthy controls were tested for the ability to secret sHLA-G. By a constant cell number (50.000/well) the number of specific spots were significantly (p < 0.001) increased in monocytes (mean: 79.8 ± 13.2 SEM) compared to CD8 (17.1 ± 7.1 SEM) and CD4 T cells (15.3 ± 9.4 SEM) suggesting that monocytes are the main producers of sHLA-G in the peripheral blood of healthy individuals. We have developed a uniform approach for DRB1, DPB1 and DQB1 SBT.
Design requirements were that the assays be easy to use and amenable to high and low throughput with a minimal number of ambiguities. The general strategy for each of these assays is a single amplification followed by 3 sequencing reactions.
Our most recent Class II assay is a DQB1 single tube PCR that amplifies both exons 2 and 3. The exon 2 PCR amplifies all DQB1 alleles and is sequenced in both the forward and reverse directions. The exon 3 PCR amplifies only DQB1*02 and *03 alleles and is sequenced in the forward direction only. The allele specific exon 3 amplification is included to eliminate the majority of DQB1 ambiguities which are DQB1*0201 or *0202 and DQB1*0301 or *0309. While the exon 3 results will be uninformative in some cases, we have found that it is far less time consuming to run the exon 3 sequence initially rather than retrospectively. To take advantage of this streamlined approach, reactions were set up using repeat and multi-channel pipettors and sequence data was generated on an ABI 3100 (16 capillary) DNA sequencer. This DQB1 method has been validated using 50 DNAs from the UCLA DNA exchange, representing all common DQB1 alleles. Examples of unique alleles that were included in the panel are DQB1* 0611 and *0309, the DQB1*0309 containing a 3 base pair deletion in exon 3.
The successful validation of this DQB1 assay has proven that DRB1, DPB1 and DQB1 SBT can be accomplished using a single uniform approach.
THE STRUCTURE OF THE 5' PART OF INTRON 2 GIVES NEW INSIGHT IN THE EVOLUTION OF HLA-DQB1
Holger-A. Elsner, Sabine Kriens, Rainer Blasczyk. Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany
The structure of the non-coding regions may deliver invaluable information about the evolution of HLA genes. In this study we have sequenced 500 bp of the 5' part of the large intron 2 of HLA-DQB1. The study was based on 30 samples of varied ethnic origin, representing 16 DQB1 alleles. Phylogenetic relationships and evolutionary parameters were computed of intron 2 and exon 2. For most alleles, the dendrograms showed clear lineage specificity; however DQB1*0301 and DQB1*0601 clustered distinct from the other variants of the respective allelic groups. Since a similar relationship was previously observed in intron 1, the two alleles thus might represent independent lineages. Accordingly, one might speculate that these variants have obtained their "DQ3" or "D Q6" character through exonic recombination with members of the DQ3 or DQ6 "core families". Another exception from lineage specificity is given by the other DQB1*03 alleles, which cluster together with the alleles of the DQB1*04 group. This finding is likely to indicate previous recombination in exon 2 leading to subsequent homogenization of intron 2 through genetic drift. The study of nucleotide substitution rates yielded no further evidence for enhanced exonic recombination since, unlike in the case of overdominant selection, the synonymous nucleotide substitution rate s in exon 2 (0.09729) did not exceed π in intron 2 (0.10784). In conclusion, the structure of intron 2 supports the idea that DQB1 is subjected to moderate evolutionary pressure, which might reflect the evolutionary strategy to generate DQ antigen diversity both by interallelic recombination and by haplotype diversity in the linkage with DQA1.
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Poster Group I -Genomic Analysis of MHC and Related Genes
